After Sanofi (SNY) announced its intention to acquire Blueprint Medicines (BPMC) for $9.1B in equity value and up to $9.5B including a contingent value right, BofA analyst Sachin Jain believes the deal looks “sensible” given it is a deal size broadly in-line with Sanofi’s communication; Adds a rare asset in Ayvakit and an early stage immunology asset, both of which are areas of Sanofi expertise; and it is an “acceptable deal valuation.” The firm’s initial deal accretion model suggests low single digit percentage EPS dilution for FY26 and approximately mid-single digit accretion at peak, adds the analyst, who has a Buy rating and EUR 123 price target on Sanofi shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi exercises license extension option to Nurix’s STAT6 program
- Sanofi to Acquire Blueprint Medicines for $9.5 Billion, Expanding Rare Disease Portfolio
- Sanofi resumed with an Equal Weight at Morgan Stanley
- Sanofi to acquire Blueprint Medicines for $129 per share in cash
- Sanofi acquires Blueprint Medicines for $129 per share or $9.1B